title: Prevention by morphine of apomorphine- and oxytocin-induced penile erection and yawning: site of action in the brain.
abstract: The effect of morphine administered systemically or into the paraventricular nucleus of the hypothalamus (PVN) on penile erection and yawning induced either by oxytocin or by the dopaminergic agonist apomorphine was studied in male rats. Systemic morphine (0.5 to 5 mg/kg intraperitoneally [IP]) prevented in a dose-dependent manner penile erection and yawning induced by the intracerebroventricular injection (ICV) of oxytocin (30 ng) or by the subcutaneous (SC) administration of apomorphine (80 micrograms/kg). Morphine (0.1 to 5 micrograms), but not U-69,593 (5 micrograms), injected into the PVN 10 minutes before oxytocin or apomorphine, was found to be able to prevent penile erection and yawning induced by the unilateral PVN microinjection of oxytocin (10 ng) or apomorphine (50 ng). The morphine-induced prevention of these behavioral responses was abolished by pretreatment with naloxone (3 mg/kg IP) 15 minutes before morphine. The present results suggest that morphine prevents apomorphine- and oxytocin-induced penile erection and yawning by inhibiting the activity of oxytocinergic neurons through mu-type receptors in this hypothalamic nucleus.
authors.affiliation: B.B. Brodie Department of Neurosciences, University of Cagliari, Italy.
authors.forename: M R
authors.initials: MR
authors.lastname: Melis
authors.forename: R
authors.initials: R
authors.lastname: Stancampiano
authors.forename: G L
authors.initials: GL
authors.lastname: Gessa
authors.forename: A
authors.initials: A
authors.lastname: Argiolas
mesh_terms: D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D001058:Apomorphine / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D044482:Benzeneacetamides; D001921:Brain / Q000033:anatomy & histology / Q000187:drug effects*; D007276:Injections, Intraventricular; D008297:Male; D008845:Microinjections; D009020:Morphine / Q000008:administration & dosage / Q000494:pharmacology*; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists; D010121:Oxytocin / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D010286:Paraventricular Hypothalamic Nucleus; D010410:Penile Erection / Q000187:drug effects*; D011759:Pyrrolidines / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011957:Receptors, Opioid / Q000187:drug effects; D017450:Receptors, Opioid, mu; D015000:Yawning / Q000187:drug effects*
chemical_list: D000700:Analgesics; D044482:Benzeneacetamides; D009292:Narcotic Antagonists; D011759:Pyrrolidines; D011957:Receptors, Opioid; D017450:Receptors, Opioid, mu; D009270:Naloxone; D010121:Oxytocin; D009020:Morphine; C045444:U 69593; D001058:Apomorphine